Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer

Journal of Clinical Oncology

Volumn 28, Issue 18, 2010, Pages 2974-2981

  Yang, Sherry X ^a   Costantino, Joseph P ^a   Kim, Chungyeul ^a   Mamounas, Eleftherios P ^a   Nguyen, Dat ^a   Jeong, Jong Hyeon ^a   Wolmark, Norman ^a   Kidwell, Kelley ^a   Paik, Soonmyung ^a   Swain, Sandra M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PACLITAXEL; PROTEIN KINASE B; SERINE; ANTINEOPLASTIC AGENT; PROGESTERONE RECEPTOR;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER STAGING; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR VOLUME; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; LYMPH NODE; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SERINE; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 77954617702     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.1602     Document Type: Article

References (40)

1. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
2. De Laurentiis M, Cancello G, D'Agostino D, et al: Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials. J Clin Oncol 26:44-53, 2008
3. Montero A, Fossella F, Hortobagyi G, et al: Docetaxel for treatment of solid tumours: A systematic review of clinical data. Lancet Oncol 6:229-239, 2005 (Pubitemid 40450714)
4. Vasey PA, Jayson GC, Gordon A, et al: Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96:1682-1691, 2004 (Pubitemid 39585637)
5. Mamounas EP, Bryant J, Lembersky B, et al: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol 23:3686-3696, 2005
6. Bhaskar PT, Hay N: The two TORCs and Akt. Dev Cell 12:487-502, 2007 (Pubitemid 46523652)
7. Jacinto E, Facchinetti V, Liu D, et al: SIN1/ MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127:125-137, 2006 (Pubitemid 44466632)
8. Sarbassov DD, Guertin DA, Ali SM, et al: Phosphorylation and regulation of Akt/PKB by the rictormTOR complex. Science 307:1098-1101, 2005 (Pubitemid 40262113)
9. Sarbassov DD, Ali SM, Kim DH, et al: Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14:1296-1302, 2004 (Pubitemid 38991819)
10. Buttrick GJ, Wakefield JG: PI3-K and GSK-3: Akt-ing together with microtubules. Cell Cycle 7:2621-2625, 2008
11. Okumura E, Fukuhara T, Yoshida H, et al: Akt inhibits Myt1 in the signalling pathway that leads to meiotic G2/M-phase transition. Nat Cell Biol 4:111-116, 2002 (Pubitemid 34141476)
12. Katayama K, Fujita N, Tsuruo T: Akt/protein kinase B-dependent phosphorylation and inactivation of WEE1Hu promote cell cycle progression at G2/M transition. Mol Cell Biol 25:5725-5737, 2005 (Pubitemid 40853605)
13. Brognard J, Clark AS, Ni Y, et al: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61:3986-3997, 2001 (Pubitemid 32720961)
14. MacKeigan JP, Taxman DJ, Hunter D, et al: Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition. Clin Cancer Res 8:2091-2099, 2002 (Pubitemid 34753578)
15. Asakuma J, Sumitomo M, Asano T, et al: Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Cancer Res 63:1365-1370, 2003 (Pubitemid 36348718)
16. Swanton C, Marani M, Pardo O, et al: Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11:498-512, 2007 (Pubitemid 46856907)
17. Nakashio A, Fujita N, Rokudai S, et al: Prevention of phosphatidylinositol 3′-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Cancer Res 60:5303-5309, 2000
18. Martin M, Mackey J, Vogel C: Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer. Breast 16:S127-S131, 2007 (suppl 2)
19. McShane LM, Altman DG, Sauerbrei W, et al: Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK). J Natl Cancer Inst 97:1180-1184, 2005 (Pubitemid 41258223)
20. Paik S, Bryant J, Tan-Chiu E, et al: Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94:852-854, 2002 (Pubitemid 34705057)
21. Harvey JM, Clark GM, Osborne CK, et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481, 1999 (Pubitemid 29220854)
22. West KA, Brognard J, Clark AS, et al: Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 111:81-90, 2003 (Pubitemid 36134851)
23. Tan AR, Yang X, Hewitt SM, et al: Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 22:3080-3090, 2004 (Pubitemid 41103720)
24. Lu Y, Lin YZ, LaPushin R, et al: The PTEN/ MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene 18:7034-7045, 1999 (Pubitemid 30028874)
25. Pervin S, Singh R, Chaudhuri G: Nitric-oxideinduced Bax integration into the mitochondrial membrane commits MDA-MB-468 cells to apoptosis: Essential role of Akt. Cancer Res 63:5470-5479, 2003 (Pubitemid 37139866)
26. Bauer KD, de la Torre-Bueno J, Diel IJ, et al: Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging. Clin Cancer Res 6:3552-3559, 2000
27. Yang SX, Simon RM, Tan AR, et al: Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer. Clin Cancer Res 11:6226-6232, 2005 (Pubitemid 41262952)
28. Wedam SB, Low JA, Yang SX, et al: Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24:769-777, 2006 (Pubitemid 46622044)
29. Tsurutani J, Fukuoka J, Tsurutani H, et al: Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol 24:306-314, 2006 (Pubitemid 46622059)
30. Cappuzzo F, Magrini E, Ceresoli GL, et al: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 96:1133-1141, 2004 (Pubitemid 39207049)
31. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
32. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Statist Soc A 135:185-206, 1972
33. Cox DR: Regression models and life tables. J R Statist Soc B 34:187-220, 1972
34. Xie J, Liu C: Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data. Stat Med 24:3089-3110, 2005 (Pubitemid 41489423)
35. Kawase T, Ohki R, Shibata T, et al: PH domainonly protein PHLDA3 is a p53-regulated repressor of Akt. Cell 136:535-550, 2009
36. Franke TF, Kaplan DR, Cantley LC: PI3K: Downstream AKTion blocks apoptosis. Cell 88:435-437, 1997 (Pubitemid 27154408)
37. Haas-Kogan DA, Prados MD, Tihan T, et al: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97:880-887, 2005 (Pubitemid 41417939)
38. Pritchard KI, Messersmith H, Elavathil L, et al: HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 26:736-744, 2008 (Pubitemid 351264386)
39. Hayes DF, Thor AD, Dressler LG, et al: HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496-1506, 2007 (Pubitemid 47572635)
40. Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006